GlassScriptPhysician profile
Garrett Harp
NPI 1053677641
$995.83
in general payments reported to CMS, 2019-2025
15 companies · $610 in 2025
The $610 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $110 · 2024: $276 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $995.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $352.71 | 2024-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Insmed, INC. | $140.19 | 2024-2025 | Arikayce, Brinsupri |
| Astrazeneca Pharmaceuticals LP | $117.87 | 2023-2025 | Airsupra, Fasenra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.08 | 2023-2025 | Ofev |
| Abbvie INC. | $47.97 | 2024-2025 | |
| Inspire Medical Systems, INC. | $43.55 | 2024 | Inspire |
| Genzyme Corporation | $42.23 | 2025 | |
| Verona Pharma, INC. | $29.73 | 2025 | Ohtuvayre |
| Avadel Cns Pharmaceuticals, LLC | $27.12 | 2024 | Lumryz |
| Takeda Pharmaceuticals U.S.A., INC. | $24.14 | 2023 | Glassia |
| Pfizer INC. | $23.65 | 2025 | |
| Jazz Pharmaceuticals INC. | $23.37 | 2023 | |
| Resmed Corp | $17.57 | 2024 | |
| 3b Medical, INC. | $14.99 | 2024 | Luna |
| Mylan Specialty L.P. | $14.66 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garrett Harp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.